#ESMO26 🚀 HARMONi-GI1 | III期

🇨🇳 682例患者 | 1L晚期BTC
💊 Ivonescimab+GemCis vs Durva+GemCis

🏆 OS: 14.9 vs 12.1 mo (HR 0.75)
📈 PFS: 8.4 vs 5.8 mo (HR 0.61)
🎯 ORR: 53.8% vs 32.5%

⚠️ G3–4 AEs: 82% vs 72.3%

💡 有望成为新的1L SoC

@OncoAlert